Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72 by David MA Mann et al.
Mann et al. Acta Neuropathologica Communications 2013, 1:68
http://www.actaneurocomms.org/content/1/1/68RESEARCH Open AccessDipeptide repeat proteins are present in the p62
positive inclusions in patients with frontotemporal
lobar degeneration and motor neurone disease
associated with expansions in C9ORF72
David MA Mann1*, Sara Rollinson2, Andrew Robinson1, Janis Bennion Callister2, Jennifer C Thompson1,
Julie S Snowden1, Tania Gendron3, Leonard Petrucelli3, Masami Masuda-Suzukake4, Masato Hasegawa4,
Yvonne Davidson1 and Stuart Pickering-Brown2Abstract
Background: Cases of Frontotemporal Lobar Degeneration (FTLD) and Motor Neurone Disease (MND) associated with
expansions in C9ORF72 gene are characterised pathologically by the presence of TDP-43 negative, but p62 positive,
inclusions in granule cells of the cerebellum and in cells of dentate gyrus and area CA4 of the hippocampus.
Results: We screened 84 cases of pathologically confirmed FTLD and 23 cases of MND for the presence of p62
positive inclusions in these three brain regions, and identified 13 positive cases of FTLD and 3 of MND. All cases
demonstrated expansions in C9ORF72 by Southern blotting where frozen tissues were available. The p62 positive
inclusions in both cerebellum and hippocampus were immunostained by antibodies to dipeptide repeat proteins
(DPR), poly Gly-Ala (poly-GA), poly Gly-Pro (poly-GP) and poly Gly-Arg (poly-GR), these arising from a putative non-ATG
initiated (RAN) sense translation of the GGGGCC expansion. There was also some slight, but variable, immunostaining
with poly-AP antibody implying some antisense translation might also occur, though the relative paucity of
immunostaining could reflect poor antigen avidity on the part of the antisense antibodies. Of the FTLD cases with DPR,
6 showed TDP-43 type A and 6 had TDP-43 type B histology; one had FTLD-tau with the pathology of corticobasal
degeneration. There were no qualitative or quantitative differences in the pattern of immunostaining with antibodies
to DPR, or p62, proteins between TDP-43 type A and type B cases. Ratings for frequency of inclusions immunostained
by these poly-GA, poly-GP and poly-GR antibodies broadly correlated with those for immunolabelled by p62 antibody
in all three regions.
Conclusion: We conclude that DPR are a major component of p62 positive inclusions in FTLD and MND.
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Frontotemporal Lobar Degeneration (FTLD) is a clinical,
pathological and genetically heterogeneous condition. The
major clinical syndromes principally involve personality and
behavioural change (behavioural variant frontotemporal
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stated.(semantic dementia) or non-fluent (progressive non-fluent
aphasia) nature [1]. All three syndromes can be accompan-
ied by Motor Neurone Disease (MND) though the combin-
ation of FTD and MND is most common. Histologically,
around half of cases have tau-based pathology, half have
TDP-43-based pathology, and about 5% have FUS-based
pathology [2,3]. Importantly, around 40% of all cases have
a strong family history of similar disease, irrespective of
clinical or histological subtype [1].
By 2007, causative mutations had been identified in tau
(MAPT) [4] and progranulin (GRN) [5,6]. Nonetheless, ittd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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pendent FTD +MND kindreds demonstrated linkage to
chromosome 9 in the region 9p21.2-p13.3 [7-10]. Subse-
quently, three GWAS studies for MND [11-13], and one
for FTLD [14] identified a susceptibility locus within this
linked region, with strongest association coming from a
80 kb haplotype block containing 3 genes, MOBKL2B,
IFNK and C9ORF72. It has now been shown that this
at least some of this association is due to the presence
of a large hexanucleotide (GGGGCC) in C9ORF72 gene
in patients with both FTLD and MND [15,16]. The
expansion occurs in the first intron or the promoter
region of the gene, depending upon the transcript iso-
form in question, and can number up to as many as
1500 repeats. The expansion is found in about one in
every twelve patients with FTLD, but this varies depend-
ing on geographical region with the expansion being rare
in Asia [16].
Pathologically, most FTLD cases with the expansion
[15-20], like many non-mutational cases of FTLD [2,21,22],
show inclusion bodies within neurones (NCI) and glial
cells of the cerebral cortex and hippocampus that contain
the nuclear transcription factor, TDP-43, and are said bear
a TDP-43 histological subtype termed FTLD-TDP type B
(according to [23]), compatible with a clinical diagnosis
of FTD and MND. Others, however, show a TDP-43
histological type characterised by the presence of many
short neurites (DN) along with NCI within the outer
layers of the cerebral cortex, and termed FTLD-TDP
type A [23]. Nonetheless, irrespective of TDP-43 histo-
logical type, expansion carriers also show a unique path-
ology within the hippocampus [17] and cerebellum
[17-19,24] characterised by NCI that are TDP-43 nega-
tive, but immunoreactive to p62 protein.
P62 is a marker for proteins destined for proteasomal
degradation though the precise target protein within
such NCI remains uncertain, and the pathogenetic mech-
anism underlying the hexanucleotide expansion remains
unclear. Nonetheless, this is likely to result from one,
or a combination, of three possible mechanisms: i)
haploinsufficiency leading to loss of C9orf72 protein
[15,16], ii) the expansion might form nuclear foci of
toxic RNA and sequester other RNA-binding proteins
such as Pur Alpha (Pur α) [25], or iii) RAN (repeat asso-
ciated non ATG-initiated) translation of the expanded
repeat region may lead to the ‘inappropriate’ formation
of dipeptide repeat proteins (DPR) which may aggregate
and confer neurotoxicity [26,27].
Here, we show that DPR are at least one of the target
protein(s) within the TDP-43 negative, p62-positive
NCI in cases of FTLD associated with hexanucleotide
(GGGGCC) expansions, and that such peptides are not
associated with other histological forms, or genetic sub-
types, of FTLD.Methods
Patients
Brain tissues were available in the Manchester Brain Bank
from a series of 84 patients with FTLD and 23 with MND.
All patients were from the North West of England and
North Wales. All FTLD cases fulfilled Lund-Manchester
clinical diagnostic criteria for FTLD [28,29], and all those
with MND fulfilled El Escorial criteria [30]. All brains had
been obtained with full ethical permission following con-
sent by the next of kin.
Histological methods
Serial paraffin sections were cut (at a thickness of 6 μm)
from formalin fixed blocks of temporal cortex (with hippo-
campus) and cerebellar cortex. Sections within the series
were immunostained by routine methods for amyloid β
protein (Aβ), tau, TDP-43 and FUS proteins, employing
microwaving in 0.1 M citrate buffer, pH 6.0 for antigen
retrieval [2]. Pathologically, of the 84 patients with FTLD,
30 had FTLD-tau (9 with FTLD-tau Picks (PiD), 7 with
MAPT mutation, 11 with CBD and 3 with PSP), 52
had FTLD-TDP (24 with type A histology, 22 with type
B histology, 6 with type C histology), 1 had FTLD-FUS
(aFTLD-U) and 1 had FTLD-ni. (see [23] for definitions).
Further sections from each case within the series were
screened for the presence of p62-immunoreactive NCI
by immunostaining with p62-lck ligand (rabbit polyclonal
antibody (B D Biosciences, Oxford, UK) 1:100) employing
a standard ABC Elite kit (Vector, Burlingame, CA, USA)
with DAB as chromagen, and again microwaving in 0.1 M
citrate buffer, pH6.0 for antigen retrieval. Positive cases
were defined where p62 positive, TDP-43 negative NCI
within either the cerebellum (see [18]) or hippocampus
(see [17]) could be clearly seen under low power object-
ive (×20) and the majority of high power fields (×40)
contained at least 2 NCI. Negative cases were either com-
pletely devoid of p62 immunostaining, or small amounts
of apparently extracellular and ‘extraneous’ p62 positive
particulate material was observed in occasional high
power fields.
Dipeptide antibody staining
A non-ATG initiated translation of the expansion would
putatively result in DPRs derived from either from for-
ward (sense) (poly Gly-Pro, (poly-GP), poly Gly-Ala (poly-
GA) and poly Gly-Arg, (poly-GR)) or reverse (antisense)
(poly Ala-Pro (poly-AP), poly Pro-Gly (poly-PG) and poly
Pro-Arg (poly-PR)) directions. Consequently, we commis-
sioned a series of custom made rabbit polyclonal anti-
bodies, raised against such putatively translated proteins.
Briefly, peptides consisting of 15 repeats with an additional
N terminal cysteine were synthesised and N-terminally
conjugated to keyhole limpet haemocyanin prior to im-
munisation. All steps in the preparation were performed
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poly-GP, poly-GR, poly-AP and poly-PR proteins. How-
ever, it was not possible to generate antibodies to poly-GA
and poly-PG proteins.
Serial sections from those cases showing p62-positive
pathology, and those from 11 (non-p62 positive) cases
with other histological and genetic forms of FTLD, other
neurodegenerative disorders and healthy controls (see
Table 1) were immunostained for DPR. Antibodies were
employed in standard IHC (as above) though, in this in-
stance, antigen unmasking was performed by pressure
cooking in citrate buffer (pH 6, 10 mM) for 30 minutes,
reaching 120 degrees Celsius and >15 kPa pressure Fol-
lowing titration to determine optimal immunostaining,
antibodies were employed at dilutions of 1:500 (poly-AP
and poly-PR), 1:750 (poly-GR) or 1:2000 (poly-GP).
Further sections from the series were immunostained
with poly-GA (and poly-GP and poly-GR) antibodies
courtesy of Dr M Hasegawa. These antibodies were raised
against poly-(GA)8, poly-(GP)8 and poly-(GR)8 peptides
with cysteine at N-terminus. The peptides were conju-
gated to m-maleimidobenzoyl-N-hydrosuccinimide ester-
activated thyroglobulin. The thyroglobulin-peptide complex
(200 μg) emulsified in Freund’s complete adjuvant was
injected subcutaneously into a New Zealand White rabbit,
followed by 4 weekly injections of peptide complex emulsi-
fied in Freund’s incomplete adjuvant, starting after 2 weeks
after the first immunization. Immunoreactivities of these
antisera were characterized by ELISA as follows. The
peptide immunogens were coated onto microtiter plates.
The plates were blocked with 10% fetal bovine serum
(FBS) in PBS, incubated with the rabbit antisera diluted
in 10% FBS/PBS at room temperature for 1.5 h, followed
by incubation with HRP-goat anti-rabbit IgG (Bio-Rad) at
1:3000 dilution, and reacted with the substrate, 0.4 mg/mL
o-phenylenediamine, in citrate phosphate buffer (24 mM
citric acid, 51 mM Na2HPO4). The absorbance at 490 nm
was measured using Plate Chameleon (HIDEX). All anti-
bodies were used for imminohistochemistry at dilution
of 1:2000, and pretreated as above. Sections were also
immunostained with the anti-dipeptide repeat antibody
C9RANT [26] (gift from L Petrucelli) at 1:3000 dilution.Microscopic analysis
Sections of cerebellum and hippocampus immunostained
for p62 and each of our own 4 DPR antibodies, and the
poly-GA antibody supplied by M Hasegawa were assessed
for the presence of DPR immunostained NCI within granule
cells of the cerebellum, and dentate gyrus cells and CA4
pyramidal cells of the hippocampus at ×20 magnification.
The frequency of DPR-immunoreactive NCI was assessed
according to:
0 = no immunostained NCI present in any field.1 = very few immunostained NCI present, in some but
not all fields.
2 = a moderate number of immunostained NCI present
in each field.
3 =many immunostained NCI present affecting most
cells in each field.
4 = very many immunostained NCI present, affecting
nearly all cells in every field.
Southern blotting
Frozen brain tissue for Southern blotting was available for
most cases employed in the study. Southern blotting was
performed using a PCR DIG labelled probe adjacent to the
expansion. The PCR probe consisted of 851 bp amplicon
using the following primers, forward 5′ CCCACACCTGC
TCTTGCTA 3′; reverse 5′ CGTTCTGTGTGATTTTTA
GTGATGA 3′.
Briefly, samples were digested overnight with 20 u of XbaI
(New England Biolabs). Samples were electrophoresed in
0.8% agarose 1 xTBE gels run at 1.5 volts/cm for 18 hours.
Following standard protocols [31], gDNA was transferred
to positively charged nylon membrane. Membranes were
fixed using UV light at 365 nm for 3 minutes using a
GE Image quant 350. Membranes were hybridized and
detected as per the DIG detection Manual (Roche Applied
Science). Signals were visualised using the GE Image
quant 350 after 1 to 4 hours.
Expansion sizing and analysis
Expansion sizing was carried out using ImageQuant TL
software (Version 7, GE Healthcare) sizing the repeat num-
ber against the DIG labelled lambda Hind III labelled size
standard included on each gel (Roche Applied Science).
Positive control (gDNA isolated from the B-Lymphocyte
cell line ND06769 obtained from the NINDS Repository–
Coriell) and negative control were included on each blot,
and were required to show a band of the expected size
or no signal on hybridisation respectively for each blot
to pass quality control.
Statistical analysis
Rating data from semiquantitative asssessments was
entered into an excel spreadsheet and analysed using
Statistical Package for Social Sciences (SPSS) software
(version 17.0). Mann–Whitney test was used to compare
rating data between pairs of groups. A p-value of less than
0.05 was considered statistically significant. Regression
analysis using Intercooled Stata Version 9 (StataCorp)
was carried to out to investigate effects between repeat
length, age of onset and disease duration.
Results
Screening the 84 FTLD and 23 MND cases with p62
revealed 16 cases, 13 with FTLD (cases #1-13) and 3
Table 1 Selected clinical and pathological details of cases investigated by dipeptide immunostaining
Case M/F Clinical diagnosis Pathological diagnosis Family history Onset (y) Duration (y) Brain weight (g)
1 M FTD FTLD-TDP type A 2 brothers, 2 sisters FTD 49 9 1050
2 M FTD FTLD-TDP type A brother MND**, mother and grandmother FTD 60 8 1210
3 F FTD FTLD-TDP type A none available 59 5 1140
4 M FTD FTLD-TDP type A father dementia 64 8 1100
5 M FTD FTLD-TDP type A father similar presentation, paternal grandmother ‘AD’ 63 2 na
6 M FTD FTLD-TDP type A yes 78 4 1200
7 M FTD +MND FTLD-TDP type B ?paternal aunt said to be ‘strange’ 60 2 na
8 M FTD +MND FTLD-TDP type B mother FTD 57 2 1210
9 M FTD FTLD-TDP type B mother dementia 54 12 na
10 F FTD FTLD-TDP type B mother and sister FTD 51 19 na
11 F FTD +MND FTLD-TDP type B father ‘AD’, sister MND, paternal nephew MND 63 2 na
12 F FTD +MND FTLD-TDP type B sister MND, brother FTD, mother ‘multiple sclerosis’ 68 5 1363
13 M FTD Corticobasal degeneration father and 5 sisters had Huntington’s disease 59 70 1271
14 M MND MND brother FTD**, mother and grandmother FTD 60 5 1350
15 F MND MND none available 40 5 1330
16 M MND MND brother MND, sister FTD + MND 53 2 1250
17 M FTD FTLD-tau Pi none 69 6 na
18 F FTD FTLD-tau MAPT +16 mother: early onset dementia; brother: MND 48 15 1100
19 M Corticobasal Syndrome FTLD-tau CBD none 65 na 1020
20 M FTD FTLD-TDP A mother AD, brother AD (but with behavioural problems) 66 7 980
21 F FTD +MND FTLD-TDP B none available 50 2 1050
22 F SD FTLD-TDP C none 70 2 1522
23 F Alzheimer’s disease Alzheimer’s disease none 74 12 1220
24 M Huntington’s disease Huntington’s disease none available 48 24 na
25 M Huntington’s disease Huntington’s disease none available 56 19 1340
26 M Normal Normal control none 54* na 1720
27 F Normal Normal control none 53* na 1220
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tive, TDP-43 negative NCI within granule cells of the
cerebellum and other cerebellar cell types, and in granule
cells of the dentate gyrus, and pyramidal cells of CA4,
CA3 and CA2 regions of the hippocampus, as described
previously [17-19,24]. Twelve of the 13 FTLD cases
showed TDP-43 proteinopathy, classifiable [23] as either
type A (6 cases) or type B (6 cases): the other case had
tauopathy compatible with corticobasal degeneration (CBD)
(Table 1). Eight of the FTLD cases had presented with
bvFTD clinically, 4 with FTD+MND and one (with CBD
pathology) with a combination of FTD and corticobasal
syndrome. All MND cases bore typical TDP-43 patho-
logical changes in motor neurones of brain stem nuclei
and spinal cord (where this was available for analysis).
Frozen tissue was available for 12 of the 16 cases show-
ing p62 pathological changes in cerebellum and hippo-
campus. These included 9 cases with FTLD (cases #1-3, 7,
9-13) and all 3 cases with MND (cases #14-16) (Table 1).
All 12 of these cases demonstrated a pathological ex-
pansion in C9ORF72 by Southern blotting. Expansion
size ranged from ~5 kb (~450 repeats) to in excess of
23 kb (over 3600 repeats) (Figure 1). No expansions
were detected in cases where no p62 pathological
changes were observed. There was no correlation be-
tween repeat size and age of disease onset or duration
(see Additional file 1: Figure S1).
p62 immunostaining
In FTLD cases, on p62 immunostaining, NCI in granule
cells of the cerebellum appeared as small rounded or oat-
shaped bodies, though occasionally larger, more rounded
and solid NCI were observed (Figure 2a). These were
very abundant in case #1, common in cases #4, 7 and
10, moderately plentiful in cases #2 and 5, occasional in
cases #3, 8 and 12, and rare in cases #6, 9 and 11
(Table 2). Similar, more granular, NCI were usually present
in basket cells (Figure 2b), especially when granule cellFigure 1 Southern blotting of FTLD and MND cases bearing expansio
ND06769, Lane 4: 01/06 FTD case #3, Lane 5: MND case #15, Lane 6: FTD/M
case #1; Lane 10: control FTD case with tauopathy, Lane 11: FTD case #9, L
#14, Lane 15: FTD/MND case #7, Lane 20: MND case#16. Lanes 16-19 show ex
where no brain tissue was available.inclusions were frequent, but none were seen within
Golgi neurones, or within Bergmann glia. In some cases,
occasional Purkinje cells (Figure 2c) and neurones in the
dentate nucleus (Figure 2d) contained small, spicular or
granular p62-immunoreactive structures, but these were
not immunoreactive with TDP-43 antibodies. In most
cases, occasional cells resembling astrocytes were seen
to contain p62 immunoreactive intranuclear inclusions,
these being located deep in the granule cell layer. All
cases also showed abundant, small, rounded NCI within
granule cells of the dentate gyrus (Figure 2e), along with
spicular or granular inclusions within pyramidal cells of
areas CA2/3 and CA4 (Figure 2f ), less commonly in
CA1 and subiculum (Table 2).
In MND cases, cerebellar granule cell NCI were abun-
dant in cases #14 and 16, but were rare in case #15
(Table 2). In all cases, p62 positive NCI were also ob-
served within granule cells of the dentate gyrus, and
similar (to FTLD cases) small, spicular or granular p62-
immunoreactive inclusions were seen within pyramidal
cells of areas CA2/3 and CA4, less commonly in CA1
and subiculum. Both of these kinds of changes were
occasionally present in cases #14 and 15 but were moder-
ately common in case #16 (Table 2).
In all FTLD and MND cases variable, but often many,
pyramidal neurones, chiefly within the deeper layers of
the adjoining cerebral (temporal) cortex also contained
NCI similar to those in the hippocampus CA regions
(not shown).
DPR immunostaining
Results of immunostaining for DPR are shown in Table 2.
All FTLD and MND cases showed similar patterns of
immunostaining though there were quantitative differ-
ences between cases with respect to the number of inclu-
sions immunostaining.
As with p62 immunostaining, immunostaining with both
our own custom anti poly-GP and poly GR antibodies andns in C9ORF72. Lane 1: Marker, Lane 2: Negative control brain, Lane 3:
ND case #11, Lane 7: FTD case #10, Lane 8: CBD case #13, Lane 9: FTD
ane 12: FTD/MND case #12, Lane 13: FTD case #2; Lane 14: MND case




Figure 2 Immunostaining of the cerebellum and hippocampus for p62 proteins shows neuronal cytoplasmic inclusions in granular
neurones (a), basket cells (b), Purkinje cells (c) and cells of the dentate nucleus (d) of the cerebellum, and in dentate gyrus granule
cells (e) and pyramidal cells of CA4 region (f). Immunoperoxidase–haematoxylin. All × 40 microscope objective magnification.
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granule cells of the cerebellum, as did Hasegawa’s poly-GA
antibody (Figure 2a). Again, more granular looking NCI
were usually present in basket cells (Figure 2b), occasionally
in Purkinje cells (Figure 2c) and neurones in the dentate
nucleus (Figure 2d), but none were seen within Golgi
neurones, or within Bergmann glia. A punctate, or fila-
mentous, staining was also seen within the molecular
layer of the cerebellum, this probably relating to parallel
projection fibres (Figure 3a and b). No nuclear inclu-
sions in atrocytes immunostained with p62 appeared to
be detected by poly-GA antibody. All FTLD and MNDcases also showed abundant, small, rounded NCI within
granule cells of the dentate gyrus (Figure 3e), along with
spicular or granular inclusions within pyramidal cells of
areas CA2/3 and CA4 (Figure 3f ), but these were less
commonly seen in CA1 and subiculum (Table 2).
Our own custom antibody raised against poly-AP showed
rare, and weak, immunostaining of NCI within CA4
neurone in occasional cases were (Table 2), similar in
appearance to those seen in such cells on p62 immuno-
staining, or with poly-GA, poly-GP and poly GR anti-
bodies. The antibody to poly-PR did not stain NCI in any
case, but strongly immunostained chromatin granules,
Table 2 Ratings for p62 and DPR antibody immunostaining of neuronal cytoplasmic inclusions for all 15 cases with expansions in C9ORF72
Case CA4 DG GCC
p62 poly-GA poly-GP poly-GR poly-PR poly-AP p62 poly-GA poly-GP poly-GR poly-PR poly-AP p62 poly-GA poly-GP poly-GR poly-PR poly-AP
1* 2 2 3 3 0.5 0.5 1 2 0 0.5 0.5 0.5 4 4 3 0.5 0 0
2* 3 3 2 3 0.5 1 2 2 0.5 2 0.5 1 2 3 3 0 0 0
3* 3 3 3 2 0.5 0.5 4 3 3 0 0 0 1 4 2 2 0 0
4* 2 2 3 3 0.5 0 3 2 3 0 0.5 0 3 3 3 0 0 0
5* 2 1 3 3 0.5 0.5 3 3 2 0 0 0 2 3 3 1 0 0
6* 1 2 2 1 0 0 1 2 2 0 0 0 1 1 1 0 0 0
7** 3 3 3 3 0 0 3 3 2 0 0 0 4 4 4 0 0 0
8** na na na na na na na na na na na na 1 1 1 0 0 0
9** 3 2 3 3 0.5 0.5 1 2 1 0.5 0 0 0.5 3 1 0 0 0
10** 3 2 2 2 0.5 0.5 4 3 3 1 0.5 0 3 3 2 0 0 0
11** 3 3 3 3 0 0 4 3 2 2 0 1 0.5 3 2 1 0.5 0
12** 3 3 2 3 0 0 4 3 1 1 0 0 1 3 3 1 1 0
13 0 2 2 2 0 0 0 2 2 0 0 0 1 1 1 0 0 0
14 3 2 3 3 0 1 1 2 2 0 0 0 3 4 2 0 0 0
15 1 1 1 1 0 0 2 2 2 2 0 0 1 1 1 0 0 0
16 2 2 2 0 0 0 2 2 2 2 0 0 3 3 3 0 0 0
Cases #1-6 had FTLD TDP-43 type A histology (*), cases #7-12 had FTLD TDP-43 type B histology (**), case #13 had corticobasal degeneration, and cases #14-16 had Motor Neurone Disease.

























Figure 3 Immunostaining of the cerebellum and hippocampus for poly-GA protein shows neuronal cytoplasmic inclusions in granular
neurones (a), basket cells (b), Purkinje cells (c) and cells of the dentate nucleus (d) of the cerebellum, and in dentate gyrus granule
cells (e) and pyramidal cells of CA4 region (f), similar to those seen on p62 immunostaining. Immunoperoxidase–haematoxylin. All × 40
microscope objective magnification.
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of hippocampus in some cases bearing expansions in
C9ORF72 (Figure 4). However, not all expansion bearers
showed any such immunostaining, nor did any of the
control cases.
The pattern of immunolabelling of NCI with C9RANT
antibody in cerebellum and hippocampus mirrored that
reported by others [26], and again appeared to be identi-
cal to that seen with both our own poly GP antibody
and that prepared by M Hasegawa (not shown).
In all expansion carriers, variable numbers of, but often
many, pyramidal neurones within the deeper layers of theadjoining cerebral (temporal) cortex also contained NCI
immunostaining with antibodies to DPR in a similar fash-
ion to those in the hippocampus CA regions (not shown).
Cases of FTLD of other histological or genetic sub-
types showed no immunostaining of TDP-43 positive NCI,
DN or NII, or of tau positive structures (Pick bodies, neuro-
fibrillary tangles). The non-demented control cases showed
no relevant DPR immunostaining, and the NII within the
HD cases were also unstained by any DPR antibody.
In all instances, immunostaining of NCI with anti-DPR
antibodies was robust. There were no apparent effects
of variable post mortem delay or prolonged fixation upon
a b
Figure 4 Immunostaining of Pukinje cells of the cerebellum (a) and pyramidal cells of CA4 region of hippocampus (b) for poly-PR
protein shows strong immunoreactivity of chromatin. Note lack of staining of NCI in either cell type. Immunoperoxidase–haematoxylin.
All × 40 microscope objective magnification.
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that had been stored in formalin for up to 20 years before
new blocks had been taken for processing into wax
sections still showing robust immunostaining for DPR,
as did cases where post mortem delay periods had exceeded
4 days.
Comparison of p62 and DPR immunostaining between
FTLD-TDP subtypes
There were no statistically significant differences between
ratings for p62 and DPR immunostaining in either FTLD-
TDP type A or type B cases for NCI in granule cells of
the cerebellum, or for those of the dentate gyrus, and
CA4 neurones, of hippocampus.
Comparisons and correlations between p62 and DPR
immunostaining
The numbers of NCI immunostained by each DPR anti-
body did not always correspond either when compared to
p62 immunostaining, or when compared among them-
selves. Those in CA2, CA3 and CA4 of hippocampus, and
those in Purkinje cells and cells of the dentate nucleus
appeared numerically similar in p62 and DPR immuno-
staining (except for poly-AP), though it appeared from
microscopic inspection that p62-positive NCI in granule
cells of the cerebellum were not all, or always, immuno-
stained by both poly-GR and poly-GP antibodies, and
none were stained by poly-AP antibody (Table 2). In the
hippocampus only a minority of the p62-positive NCI in
the dentate gyrus were immunostained by poly-GR and
poly-GP antibodies, and again none were stained by poly
AP antibody (Table 2).
Ratings for DPR immunostaining of NCI were corre-
lated with those for each other, and those for p62 immu-
nostaining, in granule cells of cerebellum, and dentate
gyrus and CA4 neurones of hippocampus. In general,
there were significant correlations between p62, poly-GA,
poly GP and poly-GR ratings, but not with those involvingpoly-AP and poly-PR. Hence, ratings for poly-GA cor-
related significantly with those for p62 in cerebellum
(p = 0.032), dentate gyrus (p = 0.000) and CA4 (p = 0.006),
with poly-GR in CA4 region (p = 0.044) and with poly-GP
in cerebellum (p = 0.003). In CA4, ratings for poly-GP
correlated with those for poly-GR (p = 0.007). In the
cerebellum, ratings for poly-GA correlated with those
for poly-GP (p = 0.008), as did ones for poly-GR with
poly-PR (p = 0.027). Only in CA4 did poly-AP correlate
with poly-PR ratings (p = 0.014).
Other observations
Cells containing DPR did not show obvious cell loss, or
any other outward signs of neurodegeneration, whether
these were granule cells of dentate gyrus or cerebellum,
or pyramidal cells of CA regions or cerebral cortex, or
Purkinje neurones of the cerebellum. No cases with
C9ORF72 expansion showed excessive tau and Aβ path-
ology (i.e. commensurate with a pathological diagnosis
of AD) for age.
Discussion
In the present study we have observed p62 positive,
TDP-43 negative NCI within cerebellar granule cells,
and granule cells of the dentate gyrus and pyramidal
cells of the hippocampus (see [17-19,24]) in 13 of 84 (15%)
cases of FTLD and in 3 of 23 (13%) cases of MND. Interest-
ingly, all cases with expansion showed a FTD, FTD+MND
or MND clinical phenotype, and 15/16 bore appropriate
TDP-43 protein pathological changes. However, one ex-
pansion carrier with clinical FTD (case #13 in Table 1)
was of FTLD-tau with CBD pathology. This case was
described by us previously [20] and is important as it is
only the second case of CBD to be described with expan-
sion in C9ORF72 (see [32] for details of the other case),
though there was no post-mortem confirmation of CBD
in this latter instance. The present case demonstrated an
expansion in C9ORF72 both on repeat-primed PCR (not
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Although the case showed no TDP-43 pathology, DPR
were present in cells of the cerebellum and hippocam-
pus (see Table 2), though curiously those NCI in granule
cells of the cerebellum were p62-immunopositive, while
those in hippocampus dentate gyrus and CA4 regions
were not positive for p62.
None of the other cases with other histological or
genetic forms of FTLD showed p62 positive, TDP-43
negative NCI within either cerebellar granule cells or
within the hippocampus. The pathological findings de-
scribed here are therefore broadly consistent with those
previously reported by others in unselected series of
cases of FTLD and/or MND [17-19,24].
All of the 12 p62 positive cases where frozen brain tis-
sues were available for analysis showed an expansion in
C9ORF72 by Southern blotting, and are therefore con-
sistent with the suggestion [17,18] that this type of p62
pathology is pathognomic for cases of FTLD and/or
MND associated with C9ORF72 mutation. Thus, it can
be presumed that an expansion was also present in the
other four FTLD cases with relevant p62 pathology where
no southern blotting (or repeat primed PCR) was possible
due to lack of fresh frozen brain tissue. The lack of associ-
ation between expansion length and age of disease onset
or duration presumably reflects that a minimum size of
expansion is required for disease. Present data suggests
this might be around 500 repeats, and expansions be-
yond this are not additionally detrimental.
The exact target protein within the p62 immunoreactive
NCI remains uncertain. Here, we performed immunohis-
tochemistry employing antibodies to DPR putatively pro-
duced in the brain through non-ATG initiated (RAN)
translation of the expansion itself. Although double im-
munofluorescence labelling was not performed in the
present study, microscopic observations on consecutive
serial sections stained with each DPR antibody suggested
that most, if not all, of the p62-positive NCI within
Purkinje and dentate nucleus cells of the cerebellum,
and neurones of CA2, CA3 and CA4 of the hippocam-
pus are similarly immunoreactive to poly-GA, poly-GP
and poly-GR antibodies (and to a much lesser extent,
poly-AP antibody), whereas only a (variable) subset of
p62-positive NCI within granule cells of the cerebellum
and dentate gyrus appeared immunoreactive to these
antibodies. These microscopic impressions were supported
by statistical analysis showing good correlations between
ratings of inclusion body frequencies as assessed using
poly-GA, poly-GP and poly-GR antibodies. Other studies
[26,27] where double immunofluorescence labelling was
indeed performed substantiate the present observations.
None of the NCI was immunoreactive to poly-PR anti-
body, though this antibody did immunolabel chromatin
granules, especially in Purkinje cells and CA4 neurones,in some C9ORF72 expansion bearers. Although this kind
of immunostaining was not seen in any of the control
subjects in such cells, it was not consistently present in
all expansion bearers, and so the relevance of this (to
pathogenesis) remains uncertain. None of the DPR anti-
bodies were immunoreactive to any other kinds of inclu-
sions (TDP or tau) associated with other histological or
genetic forms of FTLD, or the NII containing CAG re-
peats seen in HD. These findings are consistent with those
recently reported by Mori and colleagues [27]. The pattern
of DPR immunolabelling in the cerebellum and hippo-
campus in C9ORF72 expansion bearers mirrored that
reported by Ash et al. [26], and this appeared identical
to that shown by our own poly GP antibody, and that
prepared by M Hasegawa. C9RANT antibody was raised
to a panel of dipeptide repeat immunogens [26], but judging
from the similarities between its pattern of immunolabelling
and that of our own poly-GP antibody, it might be consid-
ered that its specificity, or at least, it avidity is greatest for
the poly-GP component of the immunogen mix. The
finding of strong and consistent staining with poly-GA,
poly-GP and poly-GR antibodies suggests that most of
the aberrant translation relates to sense transcripts,
though the slight, but variable immunostaining with
poly-AP antibody implies some antisense translation might
also occur. However, it remains possible that the relative
paucity of immunostaining seen here with antibodies to
antisense transcripts reflects poor antigen avidity on the
part of the antibody rather than indicating an absence of
the relevant polypeptide with DPR inclusions per se.
Nevertheless, it appears that DPR may not be the
only proteins present within these structures since the
p62 positive inclusions have also been shown to contain
hnRNPA3 [33], and others reported the inclusions in
granule cells of the dentate gyrus and cerebellum (at least)
to be immunoreactive to ubiquilin-2 [34]. There is little
or no DPR immunostaining of TDP-43 in hippocampus
or cerebral cortex in either expansion bearers, or patients
with other histological forms of FTLD [29], consistent
with those observations of NCI based on p62 immuno-
staining [17-19,24]. Furthermore there was no immuno-
staining of NII containing expanded poly-Q stretches
in patients with HD (see also [27]). Collectively, these
findings reinforce the suggestion that p62-, DPR-positive
NCI are pathognomic for FTLD (and MND) associated
with C9ORF72 expansions.
It remains uncertain as to how these NCI containing
DPR may relate to disease pathogenesis and other fun-
damental aspects of disease pathology such as TDP-43
positive NCI and neurites. While NCI containing DPR
are located in clinically and pathologically relevant regions,
such as the hippocampus and adjacent temporal cortex,
they are actually present in cells distant from the major
TDP-43 changes (layers V and VI in cerebral cortex and
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edged that cells in the dentate gyrus of the hippocampus
may contain one or other, but rarely both, types of inclu-
sion [19,27]. Those cells containing DPR did not show
any other outward signs of neurodegeneration, whether
these being small granule cells of dentate gyrus or cerebel-
lum, or larger pyramidal cells of hippocampal CA regions,
cerebral cortex or Purkinje neurones of the cerebellum.
Likewise, there appeared to be no obvious loss (thinning
out) of granule cells in either region or depletion of cells
from hippocampal pyramidal or cerebellar Purkinje cell
layers. Moreover, such changes in the cerebellum appear
to be without functional (clinical) consequence, although
there have been reports of cerebellar atrophy in expansion
bearers [35,36].
Interestingly, there appeared to be no qualitative or
quantitative differences between either the number, or the
pattern, of DPR stained NCI between FTLD-TDP type A
and type B cases, in either hippocampus or cerebellum.
This observation begs the question as to the role of
C9ORF72 expansions in determining histological pheno-
type and their relationship to TDP-43 pathology. It is
possible that variability in repeat size may have a role in
this, but we were unable to show any obvious differences
in repeat size between Type A and type B cases by Southern
blot. Alternatively, it is possible that the expansion con-
fers an ‘additive’ effect, through induction of a process
marked by p62 pathology, which is superimposed upon
a ‘background TDP-43 proteinopathy derived through a
similar mechanism to that seen in non-expansion bearers
sharing the same TDP-43 histological phenotype. If that
were so, then it might be presumed that patients bearing
the mutation suffer a ‘double whammy’, and that the ex-
pansion plays no real part in determining the TDP-43
proteinopathy and the basic underlying disorder. How-
ever, if this ‘chance scenario’ were true, then it might be
anticipated that C9ORF72 repeat expansions might com-
monly occur in association with other disorders, though
there is little, and conflicting, evidence for this in, for ex-
ample, Alzheimer’s disease [37-43] or Parkinson’s disease
and other parkinsonian syndromes such as Corticobasal
syndrome [44-47]. Indeed, it is possible that in at least
some of these instances where an expansion has been
reported in patients with conditions other than FTLD
or MND, the underlying condition may still be FTLD,
though presenting in an atypical way [39].
Conclusion
Although it is clear that production of DPR from un-
conventional translation of the expansion is a feature of
C9ORF72 associated diseases, it is far from certain as to
whether such changes drive cell damage and loss, and
how they might relate to changes in TDP-43 function and
contribute clinical disability. It remains an open questionwhether DPR mediated changes are anything more than
a pathological ‘curiosity’, but nonetheless they appear to
provide a specific diagnostic tissue marker for the pres-
ence of the genetic expansion.
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